26,817 Results

Cancer genetic mutations not all treatable: System to rank relevance of mutations needed [ESMO Press Statement]

 Added 1 day ago

Cancer genetic mutations not all treatable: System to rank relevance of mutations needed [ESMO Press Statement]

Cancer genetic mutations not all treatable: System to rank relevance of mutations needed

Data Safety Monitoring Board positive recommendation for RESOLVE-IT Phase III trial of elafibranor to proced for NASH.- Genfit.

 Added 5 hours ago

GENFIT announced that the Data Safety Monitoring Board (DSMB) issued a new positive recommendation for the continuation of the RESOLVE-IT...

Fresenius terminates merger with Akorn Inc.

 Added 1 day ago

Fresenius has decided to terminate the company’s merger agreement with Akorn, due to Akorn’s failure to fulfill several closing conditions....

FDA Advisory Commmittee recommends baricitinib 2-mg dose to treat Rheumatoid Arthritis but not 4-mg dose.- Eli Lilly + Incyte Corpn.

 Added 5 hours ago

Eli Lilly and Company and Incyte Corporation announced that the FDA Arthritis Advisory Committee recommended approval of the 2-mg dose...

Multiple studies of Vibativ in real world settings for infections in obese or elderly patients.- Theravance BioPharma

 Added 1 day ago

Theravance Biopharma, Inc.announced that positive new data from multiple studies of Vibativ (telavancin) were presented at the 28th European Congress...

European Commission approves Mylotarg to treat acute myeloid leukemia- Pfizer.

 Added 1 day ago

Pfizer Inc. announced that the European Commission has approved Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine for the...

Four years of continuous treatment benefits were sustained by Ocrevus for relapsing multiple sclerosis patients . Genentech/Roche.

 Added 1 day ago

Genentech, a member of the Roche Group, announced that new Ocrevus (ocrelizumab) data were presented at the 70th American Academy...

Successful RESTORE- IMI 1 trial of imipenem/cilastatin/relebactam in patients with imipenem-non-susceptible bacterial infections. Merck inc.

 Added 1 day ago

Merck has announced that a pivotal Phase III study of relebactam, the company’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin,...

Load more